These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31834094)

  • 1. Metabolic Syndrome Rather Than Body Mass Index Is Associated With Treatment Response to Ketamine Infusions.
    Dale RM; Bryant KA; Thompson NR
    J Clin Psychopharmacol; 2020; 40(1):75-79. PubMed ID: 31834094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
    Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
    J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
    Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
    J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of Repeated Intravenous Ketamine in Treatment-Resistant Geriatric Depression: A Case Series.
    Bryant KA; Altinay M; Finnegan N; Cromer K; Dale RM
    J Clin Psychopharmacol; 2019; 39(2):158-161. PubMed ID: 30742589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients.
    Vidal S; Jermann F; Aubry JM; Richard-Lepouriel H; Kosel M
    J Clin Psychopharmacol; 2020; 40(6):607-610. PubMed ID: 33044358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
    Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
    Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
    J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
    Szymkowicz SM; Finnegan N; Dale RM
    J Affect Disord; 2013 May; 147(1-3):416-20. PubMed ID: 23182590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
    Wang JCC; Swainson J
    J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
    [No Abstract]   [Full Text] [Related]  

  • 12. The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use.
    Albott CS; Shiroma PR; Cullen KR; Johns B; Thuras P; Wels J; Lim KO
    J Clin Psychiatry; 2017 Mar; 78(3):e308-e309. PubMed ID: 28394513
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
    Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
    J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine.
    Singh B; Bobo WV; Rasmussen KG; Stoppel CJ; Rico JA; Schak KM; Biernacka JM; Frye MA; Vande Voort JL
    J Clin Psychiatry; 2019 Nov; 80(6):. PubMed ID: 31721482
    [No Abstract]   [Full Text] [Related]  

  • 15. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
    Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
    Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
    Thomas RK; Baker G; Lind J; Dursun S
    J Psychopharmacol; 2018 Oct; 32(10):1110-1117. PubMed ID: 30182797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance Ketamine Therapy for Treatment-Resistant Depression.
    Archer S; Chrenek C; Swainson J
    J Clin Psychopharmacol; 2018 Aug; 38(4):380-384. PubMed ID: 29912788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interest-activity symptom severity predicts response to ketamine infusion in treatment-resistant depression.
    Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Su TP
    Psychopharmacology (Berl); 2021 Mar; 238(3):857-865. PubMed ID: 33471146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.